Dr. Das is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12730 High Bluff Dr
San Diego, CA 92130- Is this information wrong?
Summary
- Dr. Satya (Nanu) Das is a medical oncologist, with a background in phase I and gastrointestinal cancer, who focuses on drug development of novel therapeutics.
Education & Training
Vanderbilt University MSCI, Clinical Investigation , 2018 - 2020
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2016 - 2018
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2013 - 2016
Emory University School of MedicineClass of 2013- University of California, BerkeleyBA, Molecular Cell Biology, 2004 - 2008
Certifications & Licensure
CA State Medical License 2014 - Present
TN State Medical License 2017 - 2023
AL State Medical License 2020 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Cornell University Pharmaceutical Management Foundations
Awards, Honors, & Recognition
- Patient Experience Award Vanderbilt University Medical Center, 2020-2022
- NCI NET Task Force Junior Member National Cancer Institute
- NCCN Neuroendocrine and Adrenal Tumors Guidelines Panel NCCN
- Join now to see all
Clinical Trials
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2020 Nov 16
- Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency Start of enrollment: 2019 Nov 04
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Start of enrollment: 2021 Oct 20
Publications & Presentations
PubMed
- The Other Side of the Waterfall.Satya Das> ;JAMA Oncology. 2023 Dec 1
- Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.Simron Singh, Thomas A Hope, Emily B Bergsland, Lisa Bodei, David L Bushnell, Jennifer A Chan, Beth R Chasen, Aman Chauhan, Satya Das, Arvind Dasari, Jaydira Del River...> ;Journal of the National Cancer Institute. 2023 Sep 7
- 1 citationsCarcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.Satya Das, Shannon S Stockton, Saamir A Hassan> ;The Oncologist. 2023 Jul 5
- Join now to see all
Journal Articles
- Harnessing the Immune System in Pancreatic CancerSatya Das, Jordan Berlin, Dana Cardin, Current Treatment Opinions in Oncology, 8/13/2018
- Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor PatientsSatya Das, Gino Pineda, Jordan Berlin, Brian Hemphill, Javid Moslehi, Anju Nohria, George Fisher, Journal of Oncology and Cancer Research, 7/26/2018
- Quality Matters: Immunotherapy and the Evolving Landscape of Advanced Cancer CareDas S, Horn L, Expert Review of Quality of Life in Cancer Care, 1/1/2017
- Join now to see all
Abstracts/Posters
- A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313].Satya Das, Jennifer Whisenant, Austin Doyle, Carmen Joseph Allegra, Jordan Berlin, GI ASCO, San Francisco, 1/2019
- Peritoneal carcinomatosis (PC) in well-differentiated (WD) small-intestinal neuroendocrine tumor (SI-NET) patients (Pts) with mesenteric tumor deposits (MTDs)Satya Das, Chanjuan Shi, Tatsuki Koyama, Yi Huang, Raul S. Gonzalez, Kamran Idrees, Christina Edwards Bailey, Jordan Berlin, GI ASCO, 1/2019
- Peritoneal carcinomatosis (PC) in well differentiated small intestinal neuroendocrine tumors (SI-NET)Satya Das, Chanjuan Shi, Tatsuki Koyama, Jordan Berlin, ASCO, Chicago, 6/2018
- Join now to see all
Lectures
- A phase II study of enterade in neuroendocrine tumor (NET) patients with quality-of-life limiting bowel movement frequency.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Neuroendocrine Tumors: An Overview2019 NCAN Tennessee NET Patient Conference - 9/14/2019
- The Role for Cell Free Circulating DNA in Detecting Secondary EGFR Mutations in Advanced Stage Non-Small Cell Lung Cancer PatientsSan Diego, CA - 1/1/2015
Other
- Phase II study of the Multikinase Inhibitor of Angiogenesis, Linifanib, in Patients with Metastatic and Refractory Colorectal Cancer Expressing Mutated KRAS - Beyond t...Das S
http://onctoday.com/beyond-the-abstracts/colorectal/47926-phase-ii-study-of-the-multikinase-inhibitor-of-angiogenesis-linifanib-in-patients-with-metastatic-and-refractory-colorectal-cancer-expressing-mutated-kras-beyond-the-abstract.html
Press Mentions
Targeted Therapy for Neuroendocrine TumorsFebruary 16th, 2023- Shifts in Neuroendocrine Cancer Clinical Trial DesignNovember 2nd, 2021
Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018April 25th, 2018- Join now to see all
Grant Support
- Neuroendocrine Tumor Research Foundation Investigator AwardNeuroendocrine Tumor Research FoundationPresent
- GI Spore Career EnhancementVanderbilt Ingram Cancer CenterPresent
- VCORCDP K12NIHPresent
Professional Memberships
- Member
- Member
- North American Neuroendocrine Tumor SocietyMember
- ECOGMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
